- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT03336645
Open-label Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Children With Status Epilepticus (Convulsive) in a Healthcare Setting in Japan
15 luglio 2020 aggiornato da: Shire
A Phase 3, Multicenter, Open-label Study to Determine the Efficacy, Safety, and Pharmacokinetics of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in the Hospital or Emergency Room
The purpose of this study is to assess the efficacy, safety and pharmacokinetics of MHOS/SHP615 administered buccally in children with status epilepticus (convulsive) in a healthcare setting.
Panoramica dello studio
Tipo di studio
Interventistico
Iscrizione (Effettivo)
25
Fase
- Fase 3
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Luoghi di studio
-
-
-
Fukuoka, Giappone, 813-0017
- Fukuoka Children's Hospital(NW)
-
Hokkaidō, Giappone, 063-0005
- NHO Hokkaido Medical Center
-
Kumamoto, Giappone, 861-1196
- Kumamoto Saishunso National Hospital
-
Nagasaki, Giappone, 856-8562
- NHO Nagasaki Medical Center
-
Niigata, Giappone, 950-2085
- NHO Nishi Niigata Chuo National Hospital
-
Obu, Giappone, 474-8710
- Aichi Children's Health and Medical Center(NW)
-
Okayama, Giappone, 700-0914
- Okayama University Hospital
-
Osaka, Giappone, 535-0022
- Nakano Children's Hospital
-
Osaka, Giappone, 594-1101
- Osaka Women's and Children's Hospital(NW)
-
Saitama, Giappone, 330-8777
- Saitama Children's Medical Center(NW)
-
Suita, Giappone, 565-0871
- Osaka University Hospital
-
Tokyo, Giappone, 187-0031
- National Center Hospital, NCNP
-
Tottori, Giappone, 683-8504
- Tottori University Hospital
-
Yamadaoka, Giappone, 565-0871
- Osaka University Hospital
-
Yokohama, Giappone, 232-0066
- Kanagawa Children's Medical Center(NW)
-
-
Fujimi
-
Kofu, Fujimi, Giappone, 400-8506
- Yamanashi Prefectural Central Hospital
-
-
Gifu Prefecture
-
Gifu, Gifu Prefecture, Giappone, 500-8717
- Gifu Prefectural General Medical Center
-
-
Hokkaido
-
Sapporo, Hokkaido, Giappone, 060-8648
- Hokkaido University Hospital
-
-
Kawadacho
-
Tokyo, Kawadacho, Giappone, 162-8666
- Tokyo Women's Medical University Hospital
-
-
Okayama Prefecture
-
Okayama, Okayama Prefecture, Giappone, 701-0304
- NHO Minami-Okayama Medical Center
-
-
Owada Shinden
-
Yachiyo, Owada Shinden, Giappone, 276-8524
- Tokyo Women's Medical University Yachiyo Medical Center
-
-
Saitama-ken
-
Saitama-shi, Saitama-ken, Giappone, 330-8503
- Jichi Children's Medical Center Tochigi
-
-
Shizuoka Prefecture
-
Shizuoka, Shizuoka Prefecture, Giappone, 420-8688
- Shizuoka Institute of Epilepsy and Neurological Disorders
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
Da 3 mesi a 18 anni (Bambino, Adulto)
Accetta volontari sani
No
Sessi ammissibili allo studio
Tutto
Descrizione
Inclusion Criteria:
- Male and female participants whose corrected gestational age is greater than or equal to (>=) 52 weeks (gestational weeks plus the number of weeks after birth) and less than (<) 18 years (and weight greater than [>] 5 kilogram [kg]), at the time of investigational product administration. If the participant's exact age is not known, the participant should be excluded.
- Parent, guardian, or legally authorized representative (LAR) of the child provides informed consent (and assent, when applicable per Shire policy and country regulations) to participate in the study prior to participation in any protocol specific procedures. The participant may be prescreened by the investigator in their clinical practice and the parent, guardian, or LAR may sign informed consent before the participant presents to the healthcare setting for treatment of the seizure.
Participant with generalized tonic-clonic SE with seizures accompanied by loss of consciousness with any of the following characteristics persistent at the time of study drug administration:
- Currently presenting with seizure (convulsive) activity and 3 or more convulsions within the preceding hour
- Currently presenting with seizure (convulsive) and 2 or more convulsions in succession without recovery of consciousness
- Currently presenting with a single seizure (convulsive) lasting >=5 mins
Exclusion Criteria:
- Female participants who are pregnant, suspected to be pregnant, or nursing.
- Subjects with major trauma, not necessarily restricted to the head, as the cause of the seizure.
- Subjects with seizures due to illegal drug or acute alcoholic intoxication.
- Subjects with known or suspected recurrent seizures due to illegal drug or alcohol withdrawal.
- Subjects with history of seizures of psychogenic origin.
- Subjects with seizures due to severe encephalitis or meningitis, as determined by the PI
- Subjects with known history of hypersensitivities, non-responsiveness or contraindications to benzodiazepines (ie, clinically significant respiratory depression, severe acute hepatic failure, myasthenia gravis, syndrome of sleep apnea, glaucoma with closed angle, use of concomitant drugs determined by the investigator to have a contraindication to the use of benzodiazepines.)
- Subjects with a known history of benzodiazepine abuse.
- Subjects who, in the judgment of the healthcare provider, have not responded to previous administrations of midazolam systemic therapies, including Midafresa and/or Dormicum.
- Subjects who need emergent surgical intervention and general anesthesia/intubation.
- Subjects with significant hypotension and cardiac dysrhythmia (example [eg], atrioventricular [AV] block of second or third degree, VT [ventricular tachycardia]).
- Subjects who have been receiving human immunodeficiency virus (HIV) protease inhibitors or HIV reverse transcriptase inhibitors.
- Subjects with current hypoglycemia (glucose <60 milligram per deciliter [mg/dL]) upon presentation at the hospital or healthcare setting.
- Subjects with severe cerebral anoxia (except cerebral palsy), in the judgment of the healthcare provider.
- Subjects have used an investigational product or been enrolled in a clinical study (including vaccine studies) that, in the investigator's opinion, may impact this Shire-sponsored study.
- Subjects has received antiseizure medication prior to arrival in the healthcare setting.
- Subjects has prior placement of a vagus nerve stimulator.
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: SHP615
Participants will receive a single age-specific dose (approximately 0.25 to 0.5 milligram per kilogram [mg/kg] as midazolam) of SHP615 oromucosal solution through buccal route upon onset of seizures.
|
La soluzione per mucosa orale SHP615 verrà somministrata come singola dose specifica per età (2,5, 5, 7,5 e 10 mg).
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Percentage of Participants With Response Rate
Lasso di tempo: From start of study drug administration up to 30 minutes post-dose
|
Response rate was defined as the percentage of participants with therapeutic success.
Therapeutic success was defined as the cessation of visible seizure activity within 10 minutes with a sustained absence of visible seizure activity for 30 minutes following a single dose of MHOS/SHP615 without the need for additional rescue medication.
|
From start of study drug administration up to 30 minutes post-dose
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Percentage of Participants Who Had Sustained Absence of Seizure Activity for at Least 1, 4 and 6 Hours
Lasso di tempo: From start of study drug administration up to 1, 4 and 6 hours post-dose
|
Percentage of participants whose seizure event stopped within 10 minutes of single dose administration of SHP615 and who had sustained absence of seizure activity for at least 1, 4, and 6 hours were reported.
|
From start of study drug administration up to 1, 4 and 6 hours post-dose
|
Number of Participants With Time to Resolution of Seizures (Convulsions)
Lasso di tempo: From start of study drug administration up to follow-up (Day 8)
|
Time to resolution of seizures (convulsions) was calculated as time from IP administration to the end of the initial seizure or administration of rescue anti-convulsant medication, whichever occurs first.
Initial seizure referred to the seizure that triggered the use of the IP.
Number of participants with time to resolution of seizures (convulsions) from the administration of SHP615 were reported.
|
From start of study drug administration up to follow-up (Day 8)
|
Number of Participants With Time to Recovery of Consciousness
Lasso di tempo: From start of study drug administration up to follow-up (Day 8)
|
Time to recovery of consciousness (in minutes) was calculated only for participants who lost consciousness pre-dose at time from investigational product administration to recovery of consciousness post-dose or administration of rescue anticonvulsant medication, whichever occurs first.
Number of participants with time to recovery of consciousness were reported.
|
From start of study drug administration up to follow-up (Day 8)
|
Percentage of Participants Who Required Additional Anticonvulsant Medication for Ongoing Status Epilepticus (SE)
Lasso di tempo: 10 minutes post-dose
|
Percentage of participants who required additional anticonvulsant medication for ongoing SE, 10 minutes after a single dose of SHP615 were reported.
|
10 minutes post-dose
|
Percentage of Participants Who Failed to Respond to the Treatment With SHP615
Lasso di tempo: 10 minutes post-dose
|
Treatment failure/non-responder was defined as participants with continuing seizure activity and/or the need for any additional rescue medication according to the participating healthcare setting protocol or guideline, for 10 mins or more after a single dose of the IP.
|
10 minutes post-dose
|
Concentration of SHP615 in Plasma at 10 Minutes (C10)
Lasso di tempo: 10 minutes post-dose
|
Concentration of SHP615 in plasma at 10 minutes were reported.
|
10 minutes post-dose
|
Maximum Plasma Concentration (Cmax) of SHP615
Lasso di tempo: 1, 3, 6 hours post-dose
|
Cmax of SHP615 in plasma were reported.
|
1, 3, 6 hours post-dose
|
Area Under the Concentration-time Curve From Time Zero to 10 Minutes (AUC0-10) of SHP615 in Plasma
Lasso di tempo: Pre-dose, 10 minutes post-dose
|
AUC0-10 of SHP615 in plasma were reported.
Here "min ng/mL" was minutes nanogram per milliliter.
|
Pre-dose, 10 minutes post-dose
|
Area Under the Concentration-time Curve From Time Zero to 60 Minutes (AUC0-60) of SHP615 in Plasma
Lasso di tempo: Pre-dose, 60 minutes post-dose
|
AUC0-60 of SHP615 in plasma were reported.
|
Pre-dose, 60 minutes post-dose
|
Area Under the Concentration-time Curve From Time Zero to 180 Minutes (AUC0-180) of SHP615 in Plasma
Lasso di tempo: Pre-dose, 180 minutes post-dose
|
AUC0-180 of SHP615 in plasma were reported.
|
Pre-dose, 180 minutes post-dose
|
Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of SHP615 in Plasma
Lasso di tempo: Pre-dose, 1, 3, and 6 hours post-dose
|
AUC(0-infinity) of SHP615 in plasma were reported.
|
Pre-dose, 1, 3, and 6 hours post-dose
|
Time at Maximum Concentration (Tmax) of SHP615 in Plasma
Lasso di tempo: 1, 3, and 6 hours post-dose
|
Tmax of SHP615 in plasma were reported.
|
1, 3, and 6 hours post-dose
|
Elimination Half-life (T1/2) of SHP615 in Plasma
Lasso di tempo: 1, 3, and 6 hours post-dose
|
T1/2 of SHP615 in plasma were reported.
|
1, 3, and 6 hours post-dose
|
Number of Participants With Respiratory Depression
Lasso di tempo: From start of study drug administration up to follow-up (Day 8)
|
Respiratory depression, included the following measures within 24 hours after administration of the IP: i) Persistent decrease in oxygen saturation to < 92 percent (%) measured at 10, 30 minutes, and 4, 6, and 24 hours post-dose (i.e, < 92 % on room air for 2 minutes or more after dosing while monitoring [per healthcare setting protocol and/or the clinical judgment of the physician]) ii) Increase in respiratory effort such that assisted ventilation is used (bag-valve-mask ventilation or endotracheal intubation).
Number of participants with respiratory depression were reported.
|
From start of study drug administration up to follow-up (Day 8)
|
Number of Participants With Aspiration Pneumonia Reported as Treatment Emergent Adverse Events (TEAEs)
Lasso di tempo: From start of study drug administration up to follow-up (Day 8)
|
TEAEs was defined as AEs that start or deteriorate on or after the date of the first dose of investigational product and no later than 3 days following the last dose of IP.
Number of participants with aspiration pneumonia identified as TEAEs were reported.
|
From start of study drug administration up to follow-up (Day 8)
|
Change From Baseline in Riker Sedation-Agitation Scale at 24 Hours Post-dose
Lasso di tempo: Baseline, 24 hours post-dose
|
Sedation-Agitation was assessed, using the "Riker Sedation-Agitation Scale" (SAS) by the following 7-point scale: 7. dangerous agitation; 6. very agitated; 5. agitated; 4. calm, cooperative; 3. sedated; 2. very sedated; 1. unarousable.
Change from baseline in riker sedation-agition scale at 24 hours post-dose were reported.
|
Baseline, 24 hours post-dose
|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Lasso di tempo: From start of study drug administration up to follow-up (Day 8)
|
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment.
TEAEs was defined as AEs that start or deteriorate on or after the date of the first dose of investigational product and no later than 3 days following the last dose of IP.
Number of participants with TEAEs were reported.
|
From start of study drug administration up to follow-up (Day 8)
|
Change From Baseline in Oxygen Saturation Percentage at 24 Hours Post-dose
Lasso di tempo: Baseline, 24 hours post-dose
|
Oxygen saturation at baseline was measured and recorded on room air.
The investigator had recorded the oxygen saturation, oxygen delivery system and amount of oxygen administered during the study.
Change from baseline in oxygen saturation percentage at 24 hours post-dose were reported.
|
Baseline, 24 hours post-dose
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio (Effettivo)
23 ottobre 2017
Completamento primario (Effettivo)
19 agosto 2019
Completamento dello studio (Effettivo)
19 agosto 2019
Date di iscrizione allo studio
Primo inviato
6 novembre 2017
Primo inviato che soddisfa i criteri di controllo qualità
6 novembre 2017
Primo Inserito (Effettivo)
8 novembre 2017
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
31 luglio 2020
Ultimo aggiornamento inviato che soddisfa i criteri QC
15 luglio 2020
Ultimo verificato
1 giugno 2020
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Manifestazioni neurologiche
- Convulsioni
- Malattie del sistema nervoso
- Stato epilettico
- Effetti fisiologici delle droghe
- Agenti neurotrasmettitori
- Meccanismi molecolari dell'azione farmacologica
- Depressori del sistema nervoso centrale
- Anestetici, per via endovenosa
- Anestetici, Generale
- Anestetici
- Agenti tranquillanti
- Psicofarmaci
- Ipnotici e sedativi
- Adiuvanti, Anestesia
- Agenti anti-ansia
- Modulatori GABA
- Agenti GABA
- Midazolam
Altri numeri di identificazione dello studio
- SHP615-301
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
SÌ
Descrizione del piano IPD
Shire provides access to the de-identified individual participant data for eligible studies to aid qualified researchers in addressing legitimate scientific objectives.
These IPDs will be provided following approval of a data sharing request, and under the terms of a data sharing agreement.
Criteri di accesso alla condivisione IPD
IPD from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.shiretrials.com
website.
For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
- ICF
- RSI
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
No
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
No
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Malattie del sistema nervoso
-
Advanced BionicsCompletatoPerdita dell'udito da grave a profonda | negli utenti adulti di Advanced Bionics HiResolution™ Bionic Ear SystemStati Uniti
Prove cliniche su SHP615
-
ShireTakeda Development Center Americas, Inc.Completato